The dopamine transporter: a crucial component regulating dopamine transmission.
Identifieur interne : 004615 ( PubMed/Corpus ); précédent : 004614; suivant : 004616The dopamine transporter: a crucial component regulating dopamine transmission.
Auteurs : M. Jaber ; S. Jones ; B. Giros ; M G CaronSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.
English descriptors
- KwdEn :
- Amphetamines (pharmacology), Animals, Brain (metabolism), Carrier Proteins (genetics), Carrier Proteins (physiology), Central Nervous System Stimulants (pharmacology), Cocaine (pharmacology), Disease Models, Animal, Dopamine (metabolism), Dopamine Plasma Membrane Transport Proteins, Dopamine Uptake Inhibitors (pharmacology), Gene Dosage, Genotype, Homeostasis (genetics), Homeostasis (physiology), Humans, Hyperkinesis (chemically induced), Hyperkinesis (genetics), Hyperkinesis (physiopathology), Membrane Glycoproteins (genetics), Membrane Glycoproteins (physiology), Membrane Transport Proteins, Mice, Mice, Knockout, Mice, Transgenic, Nerve Tissue Proteins, Parkinson Disease (physiopathology), Phenotype, Rats, Schizophrenia (drug therapy), Schizophrenia (physiopathology), Substance-Related Disorders (physiopathology).
- MESH :
- chemical , genetics : Carrier Proteins, Membrane Glycoproteins.
- chemical , metabolism : Dopamine.
- chemical , pharmacology : Amphetamines, Central Nervous System Stimulants, Cocaine, Dopamine Uptake Inhibitors.
- chemically induced : Hyperkinesis.
- drug therapy : Schizophrenia.
- genetics : Homeostasis, Hyperkinesis.
- metabolism : Brain.
- chemical , physiology : Carrier Proteins, Homeostasis, Membrane Glycoproteins.
- physiopathology : Hyperkinesis, Parkinson Disease, Schizophrenia, Substance-Related Disorders.
- Animals, Disease Models, Animal, Dopamine Plasma Membrane Transport Proteins, Gene Dosage, Genotype, Humans, Membrane Transport Proteins, Mice, Mice, Knockout, Mice, Transgenic, Nerve Tissue Proteins, Phenotype, Rats.
Abstract
The dopamine system is implicated in the control of locomotion, cognition, and endocrine function. The relative contribution of the various dopamine-related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this "genetic defect," leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter-acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.
DOI: 10.1002/mds.870120502
PubMed: 9380041
Links to Exploration step
pubmed:9380041Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The dopamine transporter: a crucial component regulating dopamine transmission.</title><author><name sortKey="Jaber, M" sort="Jaber, M" uniqKey="Jaber M" first="M" last="Jaber">M. Jaber</name><affiliation><nlm:affiliation>Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, S" sort="Jones, S" uniqKey="Jones S" first="S" last="Jones">S. Jones</name></author><author><name sortKey="Giros, B" sort="Giros, B" uniqKey="Giros B" first="B" last="Giros">B. Giros</name></author><author><name sortKey="Caron, M G" sort="Caron, M G" uniqKey="Caron M" first="M G" last="Caron">M G Caron</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9380041</idno><idno type="pmid">9380041</idno><idno type="doi">10.1002/mds.870120502</idno><idno type="wicri:Area/PubMed/Corpus">004615</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The dopamine transporter: a crucial component regulating dopamine transmission.</title><author><name sortKey="Jaber, M" sort="Jaber, M" uniqKey="Jaber M" first="M" last="Jaber">M. Jaber</name><affiliation><nlm:affiliation>Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, S" sort="Jones, S" uniqKey="Jones S" first="S" last="Jones">S. Jones</name></author><author><name sortKey="Giros, B" sort="Giros, B" uniqKey="Giros B" first="B" last="Giros">B. Giros</name></author><author><name sortKey="Caron, M G" sort="Caron, M G" uniqKey="Caron M" first="M G" last="Caron">M G Caron</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amphetamines (pharmacology)</term><term>Animals</term><term>Brain (metabolism)</term><term>Carrier Proteins (genetics)</term><term>Carrier Proteins (physiology)</term><term>Central Nervous System Stimulants (pharmacology)</term><term>Cocaine (pharmacology)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Dopamine Uptake Inhibitors (pharmacology)</term><term>Gene Dosage</term><term>Genotype</term><term>Homeostasis (genetics)</term><term>Homeostasis (physiology)</term><term>Humans</term><term>Hyperkinesis (chemically induced)</term><term>Hyperkinesis (genetics)</term><term>Hyperkinesis (physiopathology)</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (physiology)</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Nerve Tissue Proteins</term><term>Parkinson Disease (physiopathology)</term><term>Phenotype</term><term>Rats</term><term>Schizophrenia (drug therapy)</term><term>Schizophrenia (physiopathology)</term><term>Substance-Related Disorders (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Carrier Proteins</term><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amphetamines</term><term>Central Nervous System Stimulants</term><term>Cocaine</term><term>Dopamine Uptake Inhibitors</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hyperkinesis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Homeostasis</term><term>Hyperkinesis</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Carrier Proteins</term><term>Homeostasis</term><term>Membrane Glycoproteins</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hyperkinesis</term><term>Parkinson Disease</term><term>Schizophrenia</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Gene Dosage</term><term>Genotype</term><term>Humans</term><term>Membrane Transport Proteins</term><term>Mice</term><term>Mice, Knockout</term><term>Mice, Transgenic</term><term>Nerve Tissue Proteins</term><term>Phenotype</term><term>Rats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The dopamine system is implicated in the control of locomotion, cognition, and endocrine function. The relative contribution of the various dopamine-related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this "genetic defect," leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter-acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9380041</PMID><DateCreated><Year>1997</Year><Month>11</Month><Day>07</Day></DateCreated><DateCompleted><Year>1997</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>1997</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>The dopamine transporter: a crucial component regulating dopamine transmission.</ArticleTitle><Pagination><MedlinePgn>629-33</MedlinePgn></Pagination><Abstract><AbstractText>The dopamine system is implicated in the control of locomotion, cognition, and endocrine function. The relative contribution of the various dopamine-related components is not well established mainly because drugs that target the dopaminergic system often lack selectivity. The in vivo gene inactivation procedure, or knockout, enables the creation of new strains of mice lacking a specific gene. This technique has been applied recently to inactivate the expression of the plasma membrane dopamine transporter. Here we summarize the main findings obtained with these transgenic mice carrying this "genetic defect," leading to a better understanding of the relative contribution of the dopamine transporter regarding locomotor activity, regulation of the expression of peptides under the control of dopaminergic activity, and responses to various drugs targeting the dopamine system. Our results establish not only the central importance of the transporter as the key element controlling dopamine levels in the brain, but also its role as an obligatory target for the behavioral and biochemical action of amphetamine and cocaine. In addition, the genetically altered mice offer a unique model to test the specificity and selectivity of dopamine transporter-acting drugs and may provide important new concepts related to the clinical and social implications of conditions such as Parkinson's disease, schizophrenia, and drug addiction.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaber</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute Laboratories, Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Giros</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Caron</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000662">Amphetamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000662">Amphetamines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002352">Carrier Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000697">Central Nervous System Stimulants</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050483">Dopamine Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018765">Dopamine Uptake Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018628">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006706">Homeostasis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006948">Hyperkinesis</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008562">Membrane Glycoproteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D026901">Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D018345">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008822">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009419">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019966">Substance-Related Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>26</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9380041</ArticleId><ArticleId IdType="doi">10.1002/mds.870120502</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004615 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 004615 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:9380041
|texte= The dopamine transporter: a crucial component regulating dopamine transmission.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9380041" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |